The beneficial effect and safety Eldecalcitol with combined peginterferon alpha-2a plus ribavirin for chronic hepatitis C patients with osteoporosis
- Conditions
- Chronic hepatitis C with osteoporosis
- Registration Number
- JPRN-UMIN000006285
- Lead Sponsor
- Department of Hepatology, Osaka City University
- Brief Summary
Enrolled patients were few. Now, new anti-HCV drugs were available for patients with chronic hepatitis C. We decide the discontinuation of the present study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Not provided
The following patients were excluded women of childbearing potential and pregnancy, lactating women allergic to ribavirin or other nucleoside analoges an uncontrollable heart trouble( myocardial infarction, heart failure, or arrhythmia) hemoglobibopathy ( thalassemia, sickle cell disease) severe renal disease or Ccr<50mL/min severe depression or psychosomatic disorders severe liver disease autoimmune hepatitis or HBV drug allegy against interferon allergic to vaccine or biological preperations concomitant herbal medication of Sho-saiko-to history of interstitial pneumonia patients who take active vitamin D3 other than Eldecalcitol other conditions considerd inappropriate by attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method